Is Buying Cellular Biomedicine Group Inc (NASDAQ:CBMG), Having Higher Short Interest a Winning Strategy?

April 20, 2018 - By Ellis Scott

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Logo

Investors sentiment increased to 0.71 in 2017 Q4. Its up 0.46, from 0.25 in 2017Q3. It increased, as 4 investors sold Cellular Biomedicine Group, Inc. shares while 3 reduced holdings. 1 funds opened positions while 4 raised stakes. 472,598 shares or 15.99% less from 562,538 shares in 2017Q3 were reported.
Tower Capital Limited Liability Company (Trc) holds 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 453 shares. Switzerland-based Zurcher Kantonalbank (Zurich Cantonalbank) has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). California Public Employees Retirement Systems invested 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). The New York-based Bnp Paribas Arbitrage has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Bridgeway Capital Mgmt Inc owns 69,100 shares. Dimensional Fund Lp reported 21,197 shares stake. Meeder Asset accumulated 549 shares. Moreover, Deutsche Comml Bank Ag has 0% invested in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 123 shares. Barclays Public Ltd Company stated it has 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). The Pennsylvania-based Vanguard Gru Incorporated has invested 0% in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). Geode Mgmt Limited Com holds 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) for 40,805 shares. Morgan Stanley stated it has 0% of its portfolio in Cellular Biomedicine Group, Inc. (NASDAQ:CBMG). 91,332 were reported by Blackrock. 102,516 were reported by Millennium Mgmt Limited Liability Corporation. Northern Tru holds 0% or 30,904 shares.

Since April 10, 2018, it had 0 buys, and 1 insider sale for $450,832 activity.

The stock of Cellular Biomedicine Group Inc (NASDAQ:CBMG) registered an increase of 5.58% in short interest. CBMG’s total short interest was 340,500 shares in April as published by FINRA. Its up 5.58% from 322,500 shares, reported previously. With 42,100 shares average volume, it will take short sellers 8 days to cover their CBMG’s short positions. The short interest to Cellular Biomedicine Group Inc’s float is 3.92%.

The stock increased 0.60% or $0.125 during the last trading session, reaching $20.825. About 26,849 shares traded. Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) has risen 64.04% since April 20, 2017 and is uptrending. It has outperformed by 52.49% the S&P500.

Cellular Biomedicine Group Inc., a biopharmaceutical company, develops treatments for cancerous and degenerative diseases in Greater China. The company has market cap of $353.85 million. It focuses on developing and marketing cell therapies to treat serious diseases, such as cancer, orthopedic, and various inflammatory diseases, as well as metabolic diseases. It currently has negative earnings. The firm develops treatments utilizing proprietary cell based technologies, including immune cell therapy for the treatment of a range of cancers; human adipose-derived mesenchymal progenitor cells for the treatment of joint and autoimmune diseases; and tumor cell specific dendritic cell therapy.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Ratings Coverage

Among 2 analysts covering Cellular Biomedicine Group (NASDAQ:CBMG), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. Cellular Biomedicine Group had 2 analyst reports since February 1, 2018 according to SRatingsIntel. FBR Capital initiated the shares of CBMG in report on Thursday, March 8 with “Buy” rating. The stock of Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) earned “Hold” rating by Maxim Group on Thursday, February 1.

Cellular Biomedicine Group, Inc. (NASDAQ:CBMG) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: